Shares of Acelyrin tumbled after the company said it would stop developing its eye-disease treatment following results from a recent study. The stock fell 16%, to $3.39, in after-hours trading Tuesday ...
"VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," ...
In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under ...
Luigi Mangione shouts as he's brought for extradition hearing: 'Insult to intelligence of American people...' Forcibly displaced Syrians head home from Turkiye after the fall of Bashar al-Assad ...